Current HIV/AIDS Reports

, Volume 15, Issue 2, pp 172–181 | Cite as

Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era

  • Jennifer J. Chang
  • Neaka Mohtashemi
  • Debika Bhattacharya
Co-infections and Comorbidity (S Naggie, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Co-infections and Comorbidity

Abstract

Purpose of Review

The purpose of this review is to summarize the prevalence and clinical implications of the isolated anti-HBc serologic profile in HIV-infected individuals. We highlight the rare but important issue of HBV reactivation in the setting of HCV therapy and describe an approach to management.

Recent Findings

The isolated anti-HBc pattern, a profile that most often indicates past exposure to HBV with waning anti-HBs immunity, is found commonly in HIV-infected individuals, particularly those with HCV. Some large cohort studies demonstrate an association with advanced liver disease, while others do not. Conversely, meta-analyses have found an association between occult HBV infection (a component of the isolated anti-HBc pattern) and advanced liver disease and hepatocellular carcinoma in HIV-uninfected individuals. In HIV-uninfected individuals with anti-HBc positivity, HBV reactivation has been reported in patients receiving HCV therapy. This phenomenon is likely the result of disinhibition of HBV with HCV eradication.

Summary

In HIV-infected patients, the long-term liver outcomes associated with the isolated anti-HBc pattern remain to be fully elucidated, supporting the need for large cohort studies with longitudinal follow-up. HBV reactivation during HCV DAA therapy has been well-described in HIV-uninfected cohorts and can inform algorithms for the screening and management of the isolated anti-HBc pattern in this population.

Keywords

DAA HCV treatment Isolated anti-HBc Occult HBV HIV/HCV HIV infection 

Notes

Compliance with Ethical Standards

Conflict of Interest

Debika Bhattacharya collaborated on an NIH sponsored protocol involving Merck, BMS, Abbvie, and Sanofi.

Jennifer J. Chang and Neaka Mohtashemi declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Bhattacharya D, Tseng CH, Tate JP, et al. Isolated hepatitis B Core antibody is associated with advanced hepatic fibrosis in HIV/HCV infection but not in HIV infection alone. J Acquir Immune Defic Syndr. 2016;72(1):e14–7.  https://doi.org/10.1097/QAI.0000000000000941.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Blondot ML, Bruss V, Kann M. Intracellular transport and egress of hepatitis B virus. J Hepatol. 2016;64(1 Suppl):S49–59.  https://doi.org/10.1016/j.jhep.2016.02.008.CrossRefPubMedGoogle Scholar
  3. 3.
    Bowden S, Locarnini S, Chang TT, et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol. 2015;21(15):4644–51.  https://doi.org/10.3748/wjg.v21.i15.4644.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42(3):302–8.  https://doi.org/10.1016/j.jhep.2004.12.015.CrossRefPubMedGoogle Scholar
  5. 5.
    Witt MD, Lewis RJ, Rieg G, Seaberg EC, Rinaldo CR, Thio CL. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis. 2013;56(4):606–12.  https://doi.org/10.1093/cid/cis908.CrossRefPubMedGoogle Scholar
  6. 6.
    Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36(3):869–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim JW, Lee SH, Park YS, et al. Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. Intervirology. 2011;54(6):316–25.  https://doi.org/10.1159/000321450.CrossRefPubMedGoogle Scholar
  8. 8.
    Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25(1):142–63.  https://doi.org/10.1128/CMR.00018-11.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Palacios R, Mata R, Hidalgo A, et al. Very low prevalence and no clinical significance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti-HBc seropositivity: the BHOI study. HIV Clin Trials. 2008;9(5):337–40.  https://doi.org/10.1310/hct0905-337.CrossRefPubMedGoogle Scholar
  10. 10.
    Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, et al. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis. 2013;56(12):1704–12.  https://doi.org/10.1093/cid/cit166.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Neau D, Winnock M, Jouvencel AC, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis. 2005;40(5):750–3.  https://doi.org/10.1086/427882.CrossRefPubMedGoogle Scholar
  12. 12.
    Firnhaber C, Viana R, Reyneke A, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg. South Africa Int J Infect Dis. 2009;13(4):488–92.  https://doi.org/10.1016/j.ijid.2008.08.018.CrossRefPubMedGoogle Scholar
  13. 13.
    Saha D, Pal A, Sarkar N, et al. Occult hepatitis B virus infection in HIV positive patients at a tertiary healthcare unit in eastern India. PLoS One. 2017;12(6):e0179035.  https://doi.org/10.1371/journal.pone.0179035.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tsui JI, French AL, Seaberg EC, et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis. 2007;45(6):736–40.  https://doi.org/10.1086/520989.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chadwick D, Stanley A, Sarfo S, et al. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS. 2013;27(1):139–41.  https://doi.org/10.1097/QAD.0b013e3283589879.CrossRefPubMedGoogle Scholar
  16. 16.
    French AL, Hotton A, Young M, et al. Isolated hepatitis B Core antibody status is not associated with accelerated liver disease progression in HIV/hepatitis C coinfection. J Acquir Immune Defic Syndr. 2016;72(3):274–80.  https://doi.org/10.1097/QAI.0000000000000969.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36(5):681–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Shire NJ, Rouster SD, Stanford SD, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):309–14.  https://doi.org/10.1097/QAI.0b013e31802e29a9.CrossRefPubMedGoogle Scholar
  19. 19.
    Karaosmanoglu HK, Aydin OA, Nazlican O. Isolated anti-HBc among HIV-infected patients in Istanbul. Turkey HIV Clin Trials. 2013;14(1):17–20.  https://doi.org/10.1310/hct1401-17.CrossRefPubMedGoogle Scholar
  20. 20.
    Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative south African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol. 2009;81(3):406–12.  https://doi.org/10.1002/jmv.21418.CrossRefPubMedGoogle Scholar
  21. 21.
    Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20(9):1253–60.  https://doi.org/10.1097/01.aids.0000232232.41877.2a.CrossRefPubMedGoogle Scholar
  22. 22.
    Lo Re V 3rd, Wertheimer B, Localio AR, et al. Incidence of transaminitis among HIV-infected patients with occult hepatitis B. J Clin Virol. 2008;43(1):32–6.  https://doi.org/10.1016/j.jcv.2008.03.030.CrossRefPubMedGoogle Scholar
  23. 23.
    Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV cohort study. Eur J Clin Microbiol Infect Dis. 1998;17(1):6–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Liang SH, Chen TJ, Lee SS, et al. Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr. 2010;54(2):122–8.  https://doi.org/10.1097/QAI.0b013e3181daafd5.PubMedGoogle Scholar
  25. 25.
    French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis. 2007;195(10):1437–42.  https://doi.org/10.1086/515578.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Pogany K, Zaaijer HL, Prins JM, Wit FW, Lange JM, Beld MG. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retrovir. 2005;21(11):922–6.  https://doi.org/10.1089/aid.2005.21.922.CrossRefPubMedGoogle Scholar
  27. 27.
    Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45(3):238–44.  https://doi.org/10.1016/j.dld.2012.09.021.CrossRefPubMedGoogle Scholar
  28. 28.
    Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32(2):231–40.  https://doi.org/10.1111/j.1478-3231.2011.02481.x.CrossRefPubMedGoogle Scholar
  29. 29.
    Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016;22(39):8720–34.  https://doi.org/10.3748/wjg.v22.i39.8720.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59(4):696–700.  https://doi.org/10.1016/j.jhep.2013.05.043.CrossRefPubMedGoogle Scholar
  31. 31.
    Lok AS, Everhart JE, Di Bisceglie AM, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54(2):434–42.  https://doi.org/10.1002/hep.24257.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22–6.  https://doi.org/10.1056/NEJM199907013410104.CrossRefPubMedGoogle Scholar
  33. 33.
    Zignego AL, Fontana R, Puliti S, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol. 1997;51(4):313–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63(3):220–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol. 1999;58(3):201–7.CrossRefPubMedGoogle Scholar
  36. 36.
    De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95(12):3529–36.  https://doi.org/10.1111/j.1572-0241.2000.03371.x.CrossRefPubMedGoogle Scholar
  37. 37.
    Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thail. 2006;89(12):2028–34.Google Scholar
  38. 38.
    Chakvetadze C, Bani-Sadr F, Le Pendeven C, et al. Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis. 2010;50(8):1184–6.  https://doi.org/10.1086/651422.CrossRefPubMedGoogle Scholar
  39. 39.
    Piroth L, Launay O, Michel ML, et al. Vaccination against hepatitis B virus (HBV) in HIV-1-infected patients with isolated anti-HBV Core antibody: the ANRS HB EP03 CISOVAC prospective study. J Infect Dis. 2016;213(11):1735–42.  https://doi.org/10.1093/infdis/jiw011.CrossRefPubMedGoogle Scholar
  40. 40.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. August 2017. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/344/hbv.
  41. 41.
    Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166(11):792–8.  https://doi.org/10.7326/M17-0377.CrossRefPubMedGoogle Scholar
  42. 42.
    Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66(1):27–36.  https://doi.org/10.1002/hep.29135.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66(1):13–26.  https://doi.org/10.1002/hep.29109.CrossRefPubMedGoogle Scholar
  44. 44.
    Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–6.  https://doi.org/10.1016/j.cgh.2016.06.023.CrossRefPubMedGoogle Scholar
  45. 45.
    Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with Ledipasvir-Sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202–4.  https://doi.org/10.1093/cid/ciw507.PubMedGoogle Scholar
  46. 46.
    Liu CH, Liu CJ, Su TH, et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect Dis. 2017;4(1):ofx028.  https://doi.org/10.1093/ofid/ofx028.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016;21(7):605–9.  https://doi.org/10.3851/IMP3066.CrossRefPubMedGoogle Scholar
  48. 48.
    Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with Sofosbuvir and Simeprevir. Clin Infect Dis. 2015;61(8):1304–6.  https://doi.org/10.1093/cid/civ474.CrossRefPubMedGoogle Scholar
  49. 49.
    De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30.  https://doi.org/10.1016/j.jcv.2016.02.026.CrossRefPubMedGoogle Scholar
  50. 50.
    Fabbri G, Mastrorosa I, Vergori A, et al. Reactivation of occult HBV infection in an HIV/HCV co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infect Dis. 2017;17(1):182.  https://doi.org/10.1186/s12879-017-2287-y.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164.  https://doi.org/10.1186/s13256-015-0630-8.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hayashi K, Ishigami M, Ishizu Y, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9(4):252–6.  https://doi.org/10.1007/s12328-016-0657-4.CrossRefPubMedGoogle Scholar
  53. 53.
    Madonia S, Orlando E, Madonia G, Cannizzaro M. HCV/HBV coinfection: the dark side of DAAs treatment? Liver Int. 2017;37(7):1086–7.  https://doi.org/10.1111/liv.13342.CrossRefPubMedGoogle Scholar
  54. 54.
    Loggi E, Gitto S, Galli S, et al. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66–70.  https://doi.org/10.1016/j.jcv.2017.05.021.CrossRefPubMedGoogle Scholar
  55. 55.
    Kawagishi N, Suda G, Onozawa M, et al. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24(12):1098–106.  https://doi.org/10.1111/jvh.12737.CrossRefPubMedGoogle Scholar
  56. 56.
    Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34(2):404–10.  https://doi.org/10.1053/jhep.2001.26511.CrossRefPubMedGoogle Scholar
  57. 57.
    Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001;16(6):636–40.CrossRefPubMedGoogle Scholar
  58. 58.
    Zhu W, Wu C, Deng W, et al. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo. PLoS One. 2012;7(9):e45146.  https://doi.org/10.1371/journal.pone.0045146.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28(2):221–8.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Yu ML, Lee CM, Chen CL, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57(6):2135–42.  https://doi.org/10.1002/hep.26266.CrossRefPubMedGoogle Scholar
  61. 61.
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95.  https://doi.org/10.1056/NEJMoa043470.CrossRefPubMedGoogle Scholar
  62. 62.
    AASLD/IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. April 2017. www.hcvguidelines.org.
  63. 63.
    VA HIV, Hepatitis, and Public Health Pathogens Program. Recommendations for Hepatitis B Viral Infection Testing and Monitoring among HCV-Infected Veterans Being Considered for DAA Treatment. October 2016. https://www.hepatitis.va.gov/pdf/hbv-recommendations-hcv-daa-treatment.pdf.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jennifer J. Chang
    • 1
    • 2
  • Neaka Mohtashemi
    • 1
  • Debika Bhattacharya
    • 1
  1. 1.UCLA CARE Center, Division of Infectious Diseases, David Geffen School of MedicineUniversity of California, Los AngelesLos AngelesUSA
  2. 2.Department of Infectious DiseasesKaiser Permanente at Los Angeles Medical CenterLos AngelesUSA

Personalised recommendations